cases per 100,000 population) in 2000, to 440 (1.97 cases per 100,000 population) in 2001, and to 838 (3.73 cases per 100,000 population) in 2002 [13] .
Patients and methods. The results of disk diffusion tests for susceptibility to penicillin and ciprofloxacin were evaluated for 56 isolates recovered from 1994 through 2003 at National Taiwan University Hospital (Hospital A), a 2000-bed medical center located in Taipei, in northern Taiwan. For disk susceptibility testing, GC agar base with 1% defined growth supplement (Isovitalex; Becton Dickinson Microbiology Systems) was used [14] .
A total of 55 isolates recovered from patients treated at the urological outpatient departments of 3 hospitals (43 from hospital A and 4 each from 2 other hospitals) in northern Taiwan from 1999 through 2003 were preserved for this study. The MICs of 16 antimicrobial agents listed in table 1 were determined by the standard agar dilution method according to the guidelines established by the NCCLS [15, 16] . For susceptibility testing, GC agar base with 1% defined growth supplement (Isovitalex; Becton Dickinson Microbiology Systems) was used. N. gonorrhoeae ATCC 49226 was used as a control strain. All isolates were tested for b-lactamase production by the cefinase disk test (Becton Dickinson Microbiology Systems).
The primers used for the PCR amplification specific for gyrA and parC genes were the same as those used by Tanaka et al. [17] . Genotyping of 47 of the 55 N. gonorrhoeae isolates was determined by the pulsotypes generated by PFGE. These isolates included 4 ciprofloxacin-susceptible, 5 ciprofloxacin-intermediate, and 38 ciprofloxacin-resistant isolates. Extraction and purification of the genomic DNA was performed as described elsewhere [18] . The DNA was digested by the restriction enzyme speI. Isolates belonging to similar pulsotypes (i.e., with differences of р6 bands) were defined as having the same genotypes. Isolates with identical pulsosubtypes (i.e., with no band differences) were defined as having the same genosubtypes [19] .
Results. From 1994 through 2003, 56 isolates of N. gonorrhoeae were recovered from various clinical specimens (i.e., from urine specimens, urethral discharge samples, vaginal discharge samples, wound specimens, and eye discharge samples) of patients treated at Hospital A. These 56 isolates were recovered from 45 men and 5 women. Their age ranged from 19 years through 54 years. The majority (90%) of these patients had urethritis, prostatitis, or cervicitis. Two patients had ophthalmia neonatorum, and 3 had septic arthritis.
One gonococcal isolate with penicillin resistance was found Overall, 78% of these isolates were resistant to penicillin (MIC, у2 mg/mL), 78% were resistant to ciprofloxacin (MIC, у1 mg/mL), and 75% were not susceptible to trovafloxacin (MIC, у0.5 mg/mL) (table 1). b-Lactamase was found in 9 isolates (16.4%), all of which exhibited a high level of resistance to penicillin (MIC, у16 mg/mL) ( figure 2A) . Of the 43 penicillin-resistant isolates, 86.0% were also resistant to ciprofloxacin. Ciprofloxacin resistance was found in 25% of isolates ) isolates exhibiting indicated pulsotypes among 47 isolates of Neisseria gonorrhoeae collected in northern Taiwan, 1999-2003. n p 38 mL). However, 1 isolate (2%) exhibited decreased susceptibility to either cefpodoxime (MIC, у1 mg/mL) or cefuroxime (MIC, у0.5 mg/mL), 2 isolates exhibited decreased susceptibility to cefepime (MIC, у1 mg/mL), and 20 isolates (36%) were intermediate or resistant to cefixime (MIC, у2 mg/mL).
Resistance to azithromycin and clarithromycin (MIC у2 mg/ mL for each agent) was found in 15 (27.3%) and 20 (36.4%) of the isolates, respectively. Tigecycline had greater in vitro activity than tetracycline (MIC 90 , 0.5 mg/mL vs. 128 mg/mL) against the isolates.
A total of 13 mutations were found in 47 isolates of N. gonorrhoeae; 5 mutations were found in the gyrA genes, and 8 were found in the parC genes. None of the ciprofloxacin-susceptible isolates had detectable mutations. Three of the 5 ciprofloxacin-intermediate isolates (MIC, 0.12 mg/mL) had single or double mutations at codons 131 (Leu131Leu, CTCrCTG) and 139 (Leu139Leu, CTGrCTA) in the parC gene. Among 38 ciprofloxacin-resistant isolates, all had mutations at codon 91 (Ser91Phe), 35 (92.1%) had mutations at condon 95 (Asp95Gly or Asp95Aln) in the gyrA gene, and all 38 isolates possessed 3-6 mutations in the parC gene. Among the 24 isolates with a markedly high level of ciprofloxacin resistance (MIC, у16 mg/mL), all but 1 isolate had mutations at codon 91 in the gyrA gene and at codons 87 (Ser87Asn) and 131 (Leu131Leu, CTCrCTG) in the parC gene.
Among the 47 isolates genotyped by PFGE, 16 genotypes (pulsotypes I through XVI) and 12 genosubtypes (i.e., pulsosubtypes Ia [ figure 3 ). Twelve pulsotypes (pulsotypes I through XII) were found in the 38 isolates with ciprofloxacin resistance, and pulsotypes IV (10 isolates), III (5 isolates), and VI (5 isolates) were predominant. Eight isolates with an MIC of ciprofloxacin of 16 mg/mL exhibited identical genosubtypes (IVa). Four of the 5 isolates with intermediate susceptibility to ciprofloxacin and a 1 ciprofloxacin-susceptible isolate belonged to genotype III (genosubtypes IIIc and IIId).
Discussion. Our observations in the present study suggest 4 important points. First, the incidence of gonorrhea in Taiwan appears to have increased in recent years (2001) (2002) and is concentrated in the northern region of the country. Second, nearly all (94%) of our isolates were not susceptible to penicillin, and b-lactamase production was found in 16.4% of these isolates. Third, the current rate of ciprofloxacin resistance in N. gonorrhoeae in northern Taiwan (95.2% of isolates obtained in 2003) is the highest rate reported worldwide [4] [5] [6] [7] [8] [9] [10] . Finally, genotype analysis clearly denotes that several ciprofloxacin-resistant clones have disseminated in northern Taiwan. The wide diffusion of several ciprofloxacin-resistant clones (i.e., polyclonal outbreaks) partly amplified the high rate of ciprofloxacin resistance.
In the present study, all penicillinase-producing N. gonorrhoeae (PPNG) isolates exhibited a higher level of resistance to penicillin (MIC range, 16-128 mg/mL) than did non-PPNG isolates (MIC, р4 mg/mL). Some penicillin-resistant isolates were also not susceptible to macrolides and tetracycline. There are ongoing investigations of the mechanisms mediating penicillin resistance (e.g., mutations in the penA and ponA genes); cross-resistance to other agents by transformations mediated by the por, penB, penC, and mtr loci; and macrolide resistance, including efflux pump (mtr and mef genes) and other genes (erm) [20] [21] [22] [23] [24] .
Recently established guidelines for the management of gonorrhea in adults in the United States and the United Kingdom continued to recommend use of a fluoroquinolone (e.g., ofloxacin, ciprofloxacin, or levofloxacin) as a first-line option for gonorrhea therapy [1, 4] . Moreover, the failure of gonococcal infections caused by N. gonorrhoeae strains with resistance to ciprofloxacin to respond to treatment with these agents has been documented [25, 26] . A treatment regimen for gonorrhea with a clinical efficacy of !3%-5% should not be considered as a first-line option. Accordingly, fluoroquinolones no longer meet the criteria to be a first-line option for the treatment of gonorrhea in many countries, including Taiwan.
The limitations of this study include the small sample sizes obtained in a 5-year period and the probable existence of surveillance bias (because only 3 hospitals in northern Taiwan participated in the study). Ongoing susceptibility surveillance from different parts of Taiwan (as part of the 2004 program of Surveillance of Multicenter Antimicrobial Resistance in Taiwan) to determine the country-based prevalence of resistance is crucial for successful treatment and control of gonorrhea. In the interim, a cephalosporin (e.g., cefpodoxime or ceftriaxone) should be used as the first-line agent for the treatment of gonorrhea.
